Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view

An update to “novel therapeutic approaches for treatment of COVID-19”

(2021) Nikoo Hossein-khannazer et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

(2021) Paul-Albert Koenig et al.   SCIENCE

Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain

(2021) Huan Ma et al.   JOURNAL OF VIROLOGY

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody

(2021) Guillermo Valenzuela Nieto et al.   Scientific Reports

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

(2021) Markus Hoffmann et al.   EBioMedicine

Preparing for the Future — Nanobodies for Covid-19?

(2021) Ram Sasisekharan   NEW ENGLAND JOURNAL OF MEDICINE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Respiratory virus infections: Understanding COVID-19

(2020) Kanta Subbarao et al.   IMMUNITY

Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)

(2020) George Nitulescu et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Generation and design of nanobodies

(2020) Serge Muyldermans   FEBS Journal

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

(2020) Jiangdong Huo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2

(2020) Alex Renn et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2

(2020) Rocktotpal Konwarh   Frontiers in Immunology

Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2

(2020) Kuttuvan Valappil Sajna et al.   CYTOTHERAPY

The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein

(2020) Stefano A. Serapian et al.   Journal of Physical Chemistry Letters

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2

(2020) Jianbo Dong et al.   Scientific Reports

COVID-19: Targeting Proteases in Viral Invasion and Host Immune Response

(2020) Sanchit Seth et al.   Frontiers in Molecular Biosciences

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

(2020) Thomas J. Esparza et al.   Scientific Reports

Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection

(2020) Pranesh Padmanabhan et al.   PLoS Computational Biology

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

(2020) Mei-Yue Wang et al.   Frontiers in Cellular and Infection Microbiology

Controlling Cytokine Storm Is Vital in COVID-19

(2020) Lu Tang et al.   Frontiers in Immunology

Neutralizing antibodies for the treatment of COVID-19

(2020) Shibo Jiang et al.   Nature Biomedical Engineering

Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review

(2020) Hamed Zare et al.   MOLECULAR AND CELLULAR PROBES

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

(2019) Lei He et al.   Viruses-Basel

Nanobody approval gives domain antibodies a boost

(2019) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

Nanobodies that Neutralize HIV

(2019) Weiss et al.   Vaccines

The Therapeutic Potential of Nanobodies

(2019) Ivana Jovčevska et al.   BIODRUGS

Detection of Neutralizing Antibodies to Tembusu Virus: Implications for Infection and Immunity

(2019) Junfeng Lv et al.   Frontiers in Veterinary Science

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

(2018) Guangyu Zhao et al.   JOURNAL OF VIROLOGY

Selection and characterization of protective anti-chikungunya virus single domain antibodies

(2018) Jinny L. Liu et al.   MOLECULAR IMMUNOLOGY

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy

(2017) Yaozhong Hu et al.   Frontiers in Immunology

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy

(2015) M. Moreno-Sastre et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity

(2014) Eline Boons et al.   ANTIVIRAL RESEARCH

Intracellular Expression of Camelid Single-Domain Antibodies Specific for Influenza Virus Nucleoprotein Uncovers Distinct Features of Its Nuclear Localization

(2014) Joseph Ashour et al.   JOURNAL OF VIROLOGY

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Cell Penetrable Humanized-VH/VHH That Inhibit RNA Dependent RNA Polymerase (NS5B) of HCV

(2012) Kanyarat Thueng-in et al.   PLoS One

Nanobody; an Old Concept and New Vehicle for Immunotargeting

(2011) Fatemeh Rahbarizadeh et al.   IMMUNOLOGICAL INVESTIGATIONS

Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion

(2011) Bert Schepens et al.   JOURNAL OF INFECTIOUS DISEASES

Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein

(2011) Guowei Wei et al.   PLoS One

Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120

(2008) A. Forsman et al.   JOURNAL OF VIROLOGY